Catalog Products » Stable Cell Lines » Human Recombinant KIR Stable Cell Line
Manual
COAs

CHO-K1/KIR Stable Cell Line

Recombinant CHO - K1 cells stably overexpress Homo sapiens killer cell immunoglobulin like receptor, with two Ig domains and long cytoplasmic tail 1 (KIR2DL1, KIR) on the surface. The surface expression of KIR is validated by FACS analysis. This cell line is recommended for cell - based binding assay to screen antibodies against human KIR or to measure binding affinity between KIR and anti - KIR antibodies.
$8500.00
M00650

Ask us a question
Product Introduction
Product Description Recombinant CHO - K1 cells stably overexpress Homo sapiens killer cell immunoglobulin like receptor, with two Ig domains and long cytoplasmic tail 1 (KIR2DL1, KIR) on the surface. The surface expression of KIR is validated by FACS analysis. This cell line is recommended for cell - based binding assay to screen antibodies against human KIR or to measure binding affinity between KIR and anti - KIR antibodies.
Culture Properties Adherent.
Stability Stable through more than 16 passages without significant changes in assay performance or expression profile.
Size Two vials of frozen cells (>1×106 per vial in 1 mL).
Storage Store cells in liquid nitrogen immediately upon receipt. Thaw and recover cells within one year from the date received.
Back

Culture Conditions
Culture Medium Ham’s F-12K (Kaighn’s), 10% FBS, 8 μg/ml Puromycin (Cat. No. A11138-03, Life Technologies)
Complete Growth Medium Ham’s F-12K (Kaighn’s) (Cat. No. 21127-022, Life Technologies), 10% FBS (Cat. No. 10099-141, Life Technologies)
Freeze Medium-DATA 95% complete growth medium, 5% (V/V) DMSO (Cat. No. D2650, Sigma).
Back

CHO-K1/KIR Stable Cell Line

Figure 1. FACS analysis of cell surface expression of human KIR on CHO-K1/KIR cells. The CHO-K1/KIR cells (blue) and the negative control CHO-K1 cells (red) were probed using PE-conjugated anti-human CD158 antibody (Cat. No. 339505, Biolegend).

»

<
>

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.